[1]Braunwald E. Diabetes,heart failure,and renal dysfunction: the vicious circles[J]. Prog Cardiovasc Dis,2019,62(4): 298-302.
[2]Griffin SJ, James KL, Irving GJ. Impact of metformin on cardiovascular disease: a metaanalysis of randomised trials among people with type 2 diabetes[J]. Diabetologia,2017, 60(9): 1620-1629.
[3]Sano RY, Shinozaki, Ohta T. Sodiumglucose cotransporters: Functional properties and pharmaceutical potential[J]. J Diabetes Investig, 2020, 11(4): 770-782.
[4]Beitelshees AL,Leslie BR,Taylor SI. Sodiumglucose cotransporter 2 inhibitors: a case study in translational research[J]. Diabetes, 2019, 68(6): 1109-1120.
[5]Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes[J]. N Engl J Med, 2015, 373(22): 2117-2128.
[6]McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction[J]. N Engl J Med,2019,381(21): 1995-2008.
[7]Nassif ME, Windsor SL, Tang F, et al. Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: the DEFINEHF trial[J]. Circulation, 2019, 140(18): 1463-1476.
[8]Baartscheer A, Schumacher CA, Wüst RCI, et al. Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits[J]. Diabetologia, 2017, 60(3): 568-573.
[9]Uthman L, Baartscheer A, Bleijlevens B, et al. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation[J]. Diabetologia, 2018, 61(3): 722-726.
[10]Olgar Y, Tuncay E, Degirmenci S, et al. Ageingassociated increase in SGLT2 disrupts mitochondrial/sarcoplasmic reticulum Ca2+ homeostasis and promotes cardiac dysfunction[J]. J Cell Mol Med,2020,24(15): 8567-8578.
[11]Lin B, Koibuchi N, Hasegawa Y, et al. Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice[J].Cardiovasc Diabetol, 2014, 13(1): 1-15.
[12]Kusaka H,Koibuchi N,Hasegawa Y, et al. Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome[J]. Cardiovasc Diabetol,2016,15(1): 157.
[13]Lee TM,Chang NC,Lin SZ. Dapagliflozin, a selective SGLT2 inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts[J]. Free Radic Biol Med, 2017, 104: 298-310.
[14]Devenny JJ, Godonis HE, Harvey SJ, et al. Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in dietinduced obese (DIO) rats[J]. Obesity, 2012, 20(8): 1645-1652.
[15]Li CJ,Zhang M,Xue M,et al. SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart[J]. Cardiovasc Diabetol, 2019, 18(1): 15.
[16]Verma S,Rawat S,Ho KL,et al. Empagliflozin increases cardiac energy production in diabetes: novel translational insights into the heart failure benefits of SGLT2 inhibitors[J]. JACC Basic Transl Sci,2018,3(5): 575-587.
[17]Ye YM, Jia XM, Bajaj M, et al. Dapagliflozin attenuates Na+/H+ exchanger1 in cardiofibroblasts via AMPK activation[J]. Cardiovasc Drugs Ther, 2018, 32(6): 553-558.
[18]Skogestad J, Aronsen JM, Tovsrud N, et al. Coupling of the Na+/K+ATPase to Ankyrin B controls Na+/Ca2+ exchanger activity in cardiomyocytes[J]. Cardiovasc Res, 2020, 116(1): 78-90.
[19]Uthman L,Baartscheer A,Bleijlevens B,et al. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation[J]. Diabetologia,2018,61(3): 722-726.
[20]Yeves A,Ennis IL. Na+/H+ exchanger and cardiac hypertrophy[J]. Hipertens Riesgo Vasc,2020,37(1): 22-32.
[21]Habibi J,Aroor AR,Sowers JR,et al. Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes[J]. Cardiovasc Diabetol, 2017,16(1): 9.
[22]Murashige D,Jang C,Neinast M,et al. Comprehensive quantification of fuel use by the failing and nonfailing human heart[J]. Science,2020,370(6514): 364-368.
[23]Ferrannini E,Mark M,Mayoux E. CV protection in the EMPAREG OUTCOME trial: a “thrifty substrate” hypothesis[J]. Diabetes Care,2016,39(7): 1108-1114.
[24]Mller N. Ketone body, 3hydroxybutyrate: minor metabolitemajor medical manifestations[J]. J Clin Endocrinol Metab,2020,105(9): 2884-2892.
[25]Quan N,Li X,Zhang J,et al. Substrate metabolism regulated by Sestrin2mTORC1 alleviates pressure overloadinduced cardiac hypertrophy in aged heart[J]. Redox Biol,2020,36: 101637.
[26]Rahadian A,Fukuda D,Salim HM,et al. Canagliflozin prevents diabetesinduced vascular dysfunction in ApoEdeficient mice[J]. J Atheroscler Thromb,2020,27(11):1141-1151.
[27]Nakatsu Y,Kokubo H,Bumdelger B,et al. The SGLT2 inhibitor luseogliflozin rapidly normalizes aortic mRNA levels of inflammationrelated but not lipidmetabolismrelated genes and suppresses atherosclerosis in diabetic ApoE KO mice[J]. Int J Mol Sci,2017,18(8): 1704.
[28]Leng W,Ouyang X,Lei X,et al. The SGLT2 inhibitor dapagliflozin has a therapeutic effect on atherosclerosis in diabetic ApoE-/- mice[J]. Mediators Inflamm,2016,2016:6305735.
[29]AlSharea A,Murphy AJ,Huggins LA,et al. SGLT2 inhibition reduces atherosclerosis by enhancing lipoprotein clearance in Ldlr-/- type 1 diabetic mice[J]. Atherosclerosis,2018,271: 166-176.
[30]Han JH,Oh TJ,Lee G,et al. The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE-/- mice fed a western diet[J]. Diabetologia,2017,60(2): 364-376.
[31]Aroor AR,Das NA,Carpenter AJ,et al. Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness,renal resistivity index and kidney injury[J]. Cardiovasc Diabetol,2018,17(1): 108.
[32]NasiriAnsari Ν,Dimitriadis GK,Agrogiannis G,et al. Canagliflozin attenuates the progression of atherosclerosis and inflammation process in APOE knockout mice[J]. Cardiovasc Diabetol,2018,17(1): 106.
[33]Gaspari T,Spizzo I,Liu H,et al. Dapagliflozin attenuates human vascular endothelial cell activation and induces vasorelaxation: a potential mechanism for inhibition of atherogenesis[J]. Diab Vasc Dis Res,2018,15(1): 64-73.
[34]Mori K,Tsuchiya K,Nakamura S,et al. Ipragliflozininduced adipose expansion inhibits cuffinduced vascular remodeling in mice[J]. Cardiovasc Diabetol, 2019, 18(1): 83.
[35]Alshnbari AS,Millar SA,O’Sullivan SE,et al. Effect of sodiumglucose cotransporter2 inhibitors on endothelial function: a systematic review of preclinical studies[J]. Diabetes Ther, 2020, 11(9):1947-1963.
[36]Shigiyama F,Kumashiro N,Miyagi M,et al. Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with earlystage type 2 diabetes mellitus: DEFENCE study[J]. Cardiovasc Diabetol,2017,16(1): 84.
[37]Sugiyama S,Jinnouchi H,Kurinami N,et al. The SGLT2 inhibitor dapagliflozin significantly improves the peripheral microvascular endothelial function in patients with uncontrolled type 2 diabetes mellitus[J]. Inter Med,2018,15(57): 2147-2156.
[38]Takahashi H,Nomiyama T,Terawaki Y,et al. Combined treatment with DPP4 inhibitor linagliptin and SGLT2 inhibitor empagliflozin attenuates neointima formation after vascular injury in diabetic mice[J]. Biochem Biophys Rep,2019,18: 100640.
[39]Ohgaki R, Wei L, Yamada K,et al. Interaction of the sodium/glucose cotransporter SGLT2 inhibitor canagliflozin with SGLT1 and SGLT2: inhibition kinetics,sidedness of action,and transporterassociated incorporation accounting for its pharmacodynamic and pharmacokinetic features[J]. J Pharmacol Exp Ther, 2016, 358(1): 94-102.
[40]Sawa Y,Saito M,Ishida N,et al. Pretreatment with KGA2727,a selective SGLT1 inhibitor,is protective against myocardial infarctioninduced ventricular remodeling and heart failure in mice[J]. J Pharmacol Sci,2020,142(1): 16-25.
[41]Li J,Liu M,Yu H,et al. Mangiferin improves hepatic lipid metabolism mainly through its metabolitenorathyriol by modulating SIRT1/AMPK/SREBP1c signaling[J]. Front Pharmacol,2018,9: 201.
[42]Taylor SI, Blau JE, Rother KI. Possible adverse effects of SGLT2 inhibitors on bone[J]. Lancet Diabetes Endocrinol, 2015, 3(1): 8-10.
|